Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

One is the company's efforts to make the drug affordable, for example ... healthcare facilities for certain non-opioid options. Considering all of this, is Vertex a buy right now?

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Vertex's research into pain signal inhibitors enabled it to develop suzetrigine as a non-opioid alternative ... incorporated ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine ... adults with moderate-to-severe acute pain - for example, after trauma or surgery - and works by blocking ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

This new nonaddictive alternative is the first of its kind that interrupts the pain signal before it reaches the brain.